Baquiloprim-d6
Baquiloprim-d6 is the deuterated-labeled Baquiloprim (HY-19581). Baquiloprim is an orally active Antibiotic and selective inhibitor of Bacterial Dihydrofolate reductase (DHFR), with an IC50 of 19 nM against E. coli and an IC50 of 190 μM against rat liver dihydrofolate reductase. Baquiloprim is a bacteriostatic broad-spectrum antibacterial agent that acts against Gram-negative and Gram-positive bacteria. Baquiloprim inhibits glucuronidation in cultured hepatocytes. Baquiloprim can be used in research related to Pasteurella haemolytica infection, bacterial infection, Escherichia coli diarrhea, bacterial infection in pigs, and pneumonic pasteurellosis.
For research use only. We do not sell to patients.
- CAS No.: 1228182-50-0
- Formula: C17H14D6N6
- Molecular Weight:314.42
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
All Antibiotic Isoforms
More
Biological Activity
Description
Application
1. This compound can be used as a tracer
2. This compound can be used as an internal standard for quantitative analysis by NMR, GC-MS, or LC-MS.
Chemical Information
-
CAS No. 1228182-50-0
-
Unlabeled CAS 102280-35-3
-
Molecular Weight 314.42
-
Formula C17H14D6N6
-
SMILES
[2H]C([2H])([2H])N(C([2H])([2H])[2H])C(C(N=CC=C1)=C1C(CC2=CN=C(N)N=C2N)=C3)=C3C
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Research Protocol for Infectious Diseases
Infectious-disease experiments test how pathogens interact with host barriers, innate immune receptors, inflammatory signaling, pathogen replication, and tissue injury; pattern-recognition receptors such as TLRs, RIG-I-like receptors, NOD-like receptors, and inflammasomes detect microbial molecules and activate NF-κB, interferon, and cytokine responses. The central hypothesis is that infection severity reflects the balance between pathogen burden and host response: protective inflammation restricts pathogen growth, whereas excessive or mislocalized inflammation contributes to tissue damage and disease phenotype. Unresolved questions include which host pathways are protective versus pathogenic, why some infection models fail to translate to human disease, and which combined readouts best predict clinically relevant infection outcomes.
-
Cell Cytotoxicity Assay
Cytotoxicity assays are usually based on the assessment of cell membrane damage, which can also be indirectly detected by measuring cell viability. Detection methods include MTT assay, CKK-8 assay, LDH assay and ATP assay, etc.
-
Gram Staining of Tissue Sections
Gram staining of tissue sections is a histochemical technique used to differentiate Gram-positive and Gram-negative bacteria within histological specimens based on differences in bacterial cell wall structure and dye retention, adapted from classical bacteriological Gram staining into tissue-compatible “histological Gram stain” variants. In tissue applications, modifications of the Brown-Hopps and Brown-Brenn methods are commonly used to improve differentiation of microorganisms embedded within host connective tissue and to reduce overstaining or loss of Gram-negative signal, which are known limitations of earlier approaches. The principle relies on crystal violet-iodine complex retention in Gram-positive organisms and subsequent decolorization and counterstaining steps that allow contrast visualization of Gram-negative organisms against tissue background.
Purity & Documentation
References
[1]. Lewicki J, et al. Oral bioavailability and pharmacokinetics of baquiloprim in dwarf goats. Research in veterinary science. 1995 May;58(3):268-71. [Content Brief]
[2]. White G, et al. Baquiloprim, a new antifolate antibacterial: in vitro activity and pharmacokinetic properties in cattle. Research in veterinary science. 1993 May;54(3):372-8. [Content Brief]
[3]. White DG, et al. Comparison of danofloxacin with baquiloprim/sulphadimidine for the treatment of experimentally induced Escherichia coli diarrhoea in calves. The Veterinary record. 1998 Sep 05;143(10):273-6. [Content Brief]
[4]. Davies AM, et al. Pharmacokinetics of baquiloprim and sulphadimidine in pigs after intramuscular administration. Research in veterinary science. 1994 Jul;57(1):69-74. [Content Brief]
[5]. Sunderland SJ, et al. Efficacy of danofloxacin 18% injectable solution in the treatment of Escherichia coli diarrhoea in young calves in Europe. Research in veterinary science. 2003 Apr;74(2):171-8. [Content Brief]
[6]. Dassanayake L, et al. Administration of a bolus formulation of baquiloprim and sulphadimidine to calves: plasma concentration--time profiles and efficacy in suppressing experimental pneumonic pasteurellosis. Veterinary microbiology. 1994 Jan;38(3):255-62. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Keywords
- Baquiloprim-d6
- 1228182-50-0
- Isotope-Labeled Compounds
- Antibiotic
- Bacterial
- Dihydrofolate reductase (DHFR)
- pneumonic pasteurellosis
- Gram-negative bacteria
- E. coli
- Gram-positive bacteria
- rat liver dihydrofolate reductase
- sulphonamides
- bacterial dihydrofolate reductase
- escherichia coli diarrhoea
- hepatocytes
- pasteurella haemolytica infection
- Inhibitor
- inhibitor
- inhibit